Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma.

Mol Biomed · 2025 · PMC12443647 · PMID 40963072

Europe PMC DOI

hedged sentence

0.2800

closest p · 5.6× alpha

0.2800

boldest claim

The sentences

a decreasing trendp = 0.28not close (p > 0.1)

The ctDNA clearance rate (ctDNA-clearance/[ctDNA-clearance + ctDNA-nonclearance]) showed a decreasing trend with advancing pathological stage: 47.73% (21/44) in stage II, 48.57% (17/35) in stage III, and 14.29% (1/7) in stage IVA patients ( p = 0.28) (Fig. 3 g).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.